Clinical trials: Overweight and/or Obesity
- Condition Overweight and/or Obesity
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight or Obesity
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered…
- Trial name
- NCT06938269
- Testing
- MWN109 tablet
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Overweight and Obesity
Phase Ib Clinical Study of HDM1005 Injection
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)…
- Trial name
- NCT06637020
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight or Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.
- Trial name
- NCT06762600
- Testing
- HRS-4729 injection, HRS9531 injection, Acetaminophen
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy, Obesity
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product [formulation A]) and in a vial (test product [formulation B2]) in male and female trial participants…
- Trial name
- NCT07768813
- Testing
- Survodutide formulation A, Survodutide formulation B2
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.
- Trial name
- NCT07716241
- Testing
- HS-20136-2
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Participants
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
- Trial name
- NCT07911514
- Testing
- AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight and Obesity
Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage
The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes…
- Trial name
- NCT04433273
- Testing
- Electrical vestibular nerve stimulation
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Overweight and/or Obesity, Healthy Participants
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a…
- Trial name
- NCT07828197
- Testing
- HDM1005
- Where
- China
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity, Type 2 Diabetes
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes.
- Trial name
- NCT02443753
- Testing
- EndoBarrier SANS
- Where
- Malaysia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Healthy
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in…
- Trial name
- NCT05421338
- Testing
- BI 456906 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Weight Management in Adult Patients With Obesity or Overweight
Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult…
- Trial name
- NCT07205432
- Testing
- XTL6001
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai Xitaili Biomedicine Technology co., Ltd.
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity and Overweight
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.
- Trial name
- NCT06857617
- Testing
- (Part C) MET097
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Metsera, a wholly owned subsidiary of Pfizer
Obesity
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
The purposes of this study are to: Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan.
- Trial name
- NCT00842400
- Testing
- Metformin, VI-0521, Sitagliptan, Probenecid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity / Overweight
A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.
This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.
- Trial name
- NCT07794111
- Testing
- TQF6422 Injection
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer